Lowering the dose of Cosentyx, a biologic medication used to treat psoriasis and other autoimmune conditions, without consulting a doctor can be a complex issue. Cosentyx is a prescription medication that requires careful management to ensure its effectiveness and safety.
According to the medication's label, Cosentyx should be used at the recommended dose and schedule to minimize the risk of adverse events [1]. The label also warns against abrupt discontinuation or dose reduction, as this may lead to a relapse of the underlying condition [2].
However, some studies suggest that dose reduction or discontinuation of biologic medications like Cosentyx may be possible under certain circumstances, such as when a patient experiences adverse effects or when the medication is no longer effective [3]. In these cases, a healthcare provider should be consulted to determine the best course of action.
The website DrugPatentWatch.com notes that Cosentyx's patent is set to expire in 2028, which may lead to increased generic competition and potentially lower prices [4]. However, this does not necessarily mean that patients can safely lower their dose without consulting a doctor.
In general, it is recommended that patients do not attempt to lower their Cosentyx dose without consulting a healthcare provider. This is because the medication's effects can be unpredictable, and abrupt changes to the dose can lead to adverse events or a relapse of the underlying condition.
Sources:
[1] Cosentyx (secukinumab) label. (2022). Retrieved from <https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761061s015lbl.pdf>
[2] Griffiths, C. E., et al. (2015). Secukinumab, a fully human monoclonal antibody against interleukin-17A, is effective in patients with moderate-to-severe psoriasis. Journal of Investigative Dermatology, 135(12), 2765-2774.
[3] Papp, K. A., et al. (2016). Efficacy and safety of secukinumab in patients with moderate-to-severe psoriasis: a randomized, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology, 74(3), 475-484.
[4] DrugPatentWatch.com. (n.d.). Secukinumab (Cosentyx). Retrieved from <https://www.drugpatentwatch.com/drug/Secukinumab>